The efficacy and safety of HPV vaccination

Kim, Woo Jin; Kim, Sung Yob

doi:2008.6.1.55

J Med Life Sci > Volume 6(1); 2008 > Article

Journal of Medicine and Life Science 2008;6(1):55-41.
DOI: https://doi.org/10.22730/jmls.2008.6.1.55 Published online December 31, 2008.

HPV 백신의 효과와 안정성

김우진¹, 김성엽²

¹제주대학교 의과대학 의학과
²제주대학교 의과대학 산부인과학교실

The efficacy and safety of HPV vaccination

Woo Jin Kim¹, Sung Yob Kim²

¹Department of Medicine, Cheju National University, Jeju 690-756, Korea
²Department of Obstetrics and Gynecology College of Medicine, Cheju National University, Jeju 690-756, Korea

Correspondence: Sung Yob Kim, Email: mdkim66@cheju.ac.kr

Abstract

HPV vaccine was licensed for use in the United States and Europe in June 2006, and is now available in most nations. It was highly successful in reducing the incidence of precancerous cervical lesions caused by HPV-16 and HPV-18. The titer of HPV antibody was maintained during 4.5 years of the extended follow up phase. HPV prescreening before vaccination is generally not needed, because HPV vaccination has protective effect for the remaining types in infected women. Systemic clinical adverse events were reported by a similar proportion of vaccine and placebo recipients. The estimated rate of anaphylaxis following HPV vaccine is slightly higher than other vaccines. However, overall rates are very low and it may leave no serious sequelae if managed appropriately. The patient is required to be seen for about 15 minutes after vaccination.

Key Words: HPV vaccine, Gardasil, Cervarix